Home › Trial NCT02621151
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
- Trial IDNCT02621151
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorNYU Langone Health
- Enrollment60
- Start date2016-08-11
- ConditionsMuscle-invasive Urothelial Cancer of the Bladder
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.